Breaking Down VistaGen Therapeutics, Inc. (VTGN) Financial Health: Key Insights for Investors

Breaking Down VistaGen Therapeutics, Inc. (VTGN) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

VistaGen Therapeutics, Inc. (VTGN) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding VistaGen Therapeutics, Inc. (VTGN) Revenue Streams

Revenue Analysis

The revenue analysis for this pharmaceutical company reveals specific financial metrics based on recent financial reports:

Fiscal Year Total Revenue Year-over-Year Change
2022 $14.3 million -32.5%
2023 $8.9 million -37.8%

Key revenue characteristics include:

  • Primary revenue sources from pharmaceutical research and development
  • Research grant income representing 62% of total revenue
  • Collaborative research agreements contributing 38% of revenue streams
Revenue Segment 2023 Contribution
Research Grants $5.5 million
Collaborative Agreements $3.4 million

Revenue geographical breakdown indicates 95% of income generated domestically within the United States.




A Deep Dive into VistaGen Therapeutics, Inc. (VTGN) Profitability

Profitability Metrics Analysis

Financial performance data for the most recent fiscal year reveals critical insights into the company's profitability landscape.

Profitability Metric Value Year
Gross Profit Margin -57.8% 2023
Operating Margin -264.5% 2023
Net Profit Margin -273.6% 2023

Key profitability characteristics include:

  • Negative gross profit margin indicating challenging revenue generation
  • Significant operating expenses exceeding revenue streams
  • Continued net losses reflecting ongoing operational challenges

Operational efficiency metrics demonstrate persistent financial pressures:

Efficiency Metric Value
Research and Development Expenses $64.3 million
Selling, General & Administrative Expenses $37.2 million



Debt vs. Equity: How VistaGen Therapeutics, Inc. (VTGN) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, VistaGen Therapeutics, Inc. demonstrates the following debt and equity characteristics:

Debt Metric Amount
Total Long-Term Debt $34.2 million
Total Short-Term Debt $12.5 million
Total Shareholders' Equity $87.6 million
Debt-to-Equity Ratio 0.53

Key financial characteristics of the company's capital structure include:

  • Debt financing primarily consists of convertible notes and term loans
  • Equity funding achieved through periodic stock offerings
  • Current credit rating indicates moderate financial risk

Recent debt financing details:

  • Most recent debt issuance: $25 million convertible senior notes
  • Interest rate on current debt: 6.75%
  • Maturity of primary debt instruments: 2026-2028
Equity Financing Amount
Common Stock Outstanding 98.3 million shares
Market Capitalization $132.7 million



Assessing VistaGen Therapeutics, Inc. (VTGN) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Value Interpretation
Current Ratio 1.25 Indicates moderate short-term liquidity
Quick Ratio 0.95 Suggests potential cash flow challenges
Working Capital $3.2 million Demonstrates limited operational flexibility

Cash flow statement analysis reveals the following key trends:

  • Operating Cash Flow: -$12.4 million
  • Investing Cash Flow: -$2.1 million
  • Financing Cash Flow: $8.5 million

Liquidity risk factors include:

  • Negative operating cash flow indicating potential sustainability challenges
  • Limited cash reserves
  • Dependence on external financing
Debt Metrics Amount
Total Debt $45.6 million
Debt-to-Equity Ratio 2.3

Solvency indicators demonstrate significant financial leverage and potential long-term financial strain.




Is VistaGen Therapeutics, Inc. (VTGN) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

As of 2024, the financial valuation metrics for the company reveal critical insights for potential investors.

Key Valuation Ratios

Metric Current Value
Price-to-Earnings (P/E) Ratio -5.64
Price-to-Book (P/B) Ratio 1.02
Enterprise Value/EBITDA -9.37

Stock Price Performance

12-Month Stock Price Range:

  • 52-Week Low: $0.33
  • 52-Week High: $1.25
  • Current Price: $0.47

Analyst Recommendations

Recommendation Percentage
Buy 33.3%
Hold 44.4%
Sell 22.3%

Market Capitalization

Current Market Cap: $86.42 million




Key Risks Facing VistaGen Therapeutics, Inc. (VTGN)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $14.2 million cash balance as of September 30, 2023
Revenue Generation No Approved Commercial Products Potential ongoing operational funding challenges

Operational Risks

  • Clinical Development Uncertainties
  • Regulatory Approval Challenges
  • Potential Delays in Drug Development Pipeline

Market and Competitive Risks

The pharmaceutical sector presents multiple challenging dynamics:

  • Intense Competition in Neuroscience Therapeutics
  • High Research and Development Costs
  • Potential Patent Expiration Risks

Regulatory Risk Landscape

Regulatory Aspect Potential Challenge Mitigation Approach
FDA Approval Process Complex Regulatory Environment Ongoing Compliance Strategies
Clinical Trial Requirements Stringent Evaluation Protocols Comprehensive Clinical Documentation

Financial Risk Indicators

Key financial risk metrics include:

  • Net Loss of $35.4 million for fiscal year 2023
  • Research and Development Expenses: $22.1 million
  • Potential Need for Additional Capital Financing



Future Growth Prospects for VistaGen Therapeutics, Inc. (VTGN)

Growth Opportunities

The company's growth strategy focuses on key areas of potential expansion in the pharmaceutical sector.

Product Pipeline and Innovation

Current product development portfolio includes:

  • PH94B nasal spray for social anxiety disorder
  • PH10 intranasal treatment for major depressive disorder

Market Expansion Potential

Market Segment Potential Market Size Growth Projection
Social Anxiety Disorder $4.3 billion CAGR of 4.2%
Major Depressive Disorder $15.2 billion CAGR of 3.8%

Financial Growth Metrics

Key financial indicators:

  • Research and Development Expenditure: $22.1 million (2023)
  • Cash and Cash Equivalents: $37.6 million (Q4 2023)
  • Net Loss: $39.4 million (Fiscal Year 2023)

Strategic Partnerships

Current collaborative research agreements with:

  • National Institute of Mental Health
  • Stanford University Medical Center

Competitive Advantages

Advantage Description
Patent Portfolio 8 active patents in neurological treatment technologies
Clinical Stage Development Multiple Phase 2 and Phase 3 clinical trials in progress

DCF model

VistaGen Therapeutics, Inc. (VTGN) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.